Citations 1
Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
Benedict, Ágnes , Panjabi, Sumeet , Houisse, Ivan, Campioni, Marco, Giannopoulou, Andromachi, Aggarwal, Sanjay , Jakubowiak, Andrzej , Fonseca, Rafaël
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8021-8021
